Sale by Eiry Roberts of 6978 shares of Neurocrine Biosciences

NBIX Stock  USD 138.64  1.95  1.43%   
Slightly above 64% of all Neurocrine Biosciences' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Neurocrine Biosciences suggests that some traders are interested. Neurocrine Biosciences' investing sentiment can be driven by a variety of factors including economic data, Neurocrine Biosciences' earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Neurocrine Biosciences In officer. General open market or private sale of non-derivative or derivative security

Read at macroaxis.com
Neurocrine insider trading alert for sale of common stock by Eiry Roberts, Chief Medical Officer, on 14th of December 2023. This event was filed by Neurocrine Biosciences In with SEC on 2023-12-14. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Neurocrine Biosciences' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Neurocrine Biosciences' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Neurocrine Biosciences Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Neurocrine Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Neurocrine Biosciences Fundamental Analysis

We analyze Neurocrine Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurocrine Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurocrine Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Shares Outstanding

Shares Outstanding Comparative Analysis

Neurocrine Biosciences is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Neurocrine Biosciences Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Neurocrine Biosciences stock to make a market-neutral strategy. Peer analysis of Neurocrine Biosciences could also be used in its relative valuation, which is a method of valuing Neurocrine Biosciences by comparing valuation metrics with similar companies.

Peers

Neurocrine Biosciences Related Equities

IRWDIronwood Pharmaceuticals   2.27   
0%
40.0%
PCRXPacira BioSciences,   1.16   
0%
20.0%
ANIPANI Pharmaceuticals   0.73   
0%
12.0%
ALKSAlkermes Plc   0.52   
0%
9.0%
ITCIIntracellular   0.45   
0%
7.0%
DVAXDynavax Technologies   0.39   
0%
6.0%
COLLCollegium Pharmaceutical   0.29   
0%
5.0%
AMPHAmphastar   0.00   
0%
0%
PBHPrestige Brand   0.60   
10.0%
0%
SUPNSupernus Pharmaceuticals   0.74   
13.0%
0%
AVDLAvadel Pharmaceuticals   1.74   
30.0%
0%
EVOEvotec SE   5.65   
100.0%
0%

Additional Tools for Neurocrine Stock Analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.